Regulatory Setback for Eli Lilly - Analyst Blog

By
A A A

Eli Lilly and Company ( LLY ) and partner Boehringer Ingelheim suffered a regulatory setback with the U.S. Food and Drug Administration (FDA) issuing a Complete Response Letter (CRL) for their New Drug Application (NDA) for empagliflozin, investigational sodium glucose co-transporter-2 (SGLT2) inhibitor. Eli Lilly and Boehringer Ingelheim are looking to get the candidate approved for the treatment of type II diabetes.

The FDA mentioned in the CRL that the deficiencies observed previously at the Boehringer Ingelheim manufacturing facility, where empagliflozin will be produced, have to be resolved in order to gain approval for the candidate. Importantly, the agency did not ask the companies to conduct additional studies.

Eli Lilly and Boehringer Ingelheim said that they are working with the FDA to submit a response to the CRL and resolve the issues mentioned in it.

The delay in FDA's decision on empagliflozin, while disappointing, is not really surprising as the Boehringer Ingelheim manufacturing facility had already received a warning letter from the FDA and chances remained that this would delay the approval of empagliflozin.

However, Eli Lilly needs to bring new products to market considering key products like Cymbalta and Zyprexa are facing stiff generic competition. A generic version of Evista will also be launched shortly. Meanwhile, SGLT2 inhibitors like Johnson & Johnson 's Invokana ( JNJ ) and AstraZeneca 's ( AZN ) Farxiga will get a head start in the type II diabetes market.

Eli Lilly carries a Zacks Rank #3 (Hold). A better-ranked stock in the pharma sector is Novo Nordisk ( NVO ) with a Zacks Rank #2 (Buy).



ASTRAZENECA PLC (AZN): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: CRL , AZN , JNJ , LLY , NVO

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

111,864,163
  • $3.91 ▲ 2.36%
76,404,746
  • $7.37 ▼ 5.03%
66,680,057
  • $15.25 ▼ 2.12%
61,293,760
  • $30.55 ▼ 6.09%
56,394,825
    $23 unch
55,005,642
  • $95.60 ▼ 2.60%
47,372,853
  • $95.02 ▼ 2.02%
44,783,481
  • $45.19 ▼ 2.40%
As of 7/31/2014, 04:07 PM